Hikal launches HPAPI laboratory at Integrated Innovation Centre, Pune

The new cGMP-compliant HPAPI Laboratory is equipped with state-of-the-art isolators designed to meet Occupational Exposure Band 5 (OEB-5) requirements

Fredun Pharmaceuticals launches India's first pure Jain dog biscuit

This innovation reinforces Fredun's commitment to creating a 360 degree pet wellness ecosystem

Bristol Myers Squibb showcases transformative advances across oncology portfolio at ESMO 2025

Gilead and Kite to transform cancer care with new data at ESMO 2025

The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy

Roche’s Elecsys pTau181 becomes first FDA-cleared blood test to rule out Alzheimer’s pathology in primary care

New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency

Vasa Therapeutics secures FDA IND clearance to advance VS-041 into clinical trial for HFpEF

IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels

EY to acquire life science tech firm Aqurance

Acquisition strengthens EY’s Veeva Centers of Excellence, expanding clinical, regulatory, and commercial services for global pharma and biotech companies

Cadila launches allergy relief tablet Dlorfast-M

Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response

Moderna’s mRNA-4359 shows promising early results in resistant Melanoma at ESMO 2025

mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma

Relmada therapeutics appoints Dr. Max Kates to propel NDV-01 toward phase 3

Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026